Ryo Miyata
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Ryo Miyata has a total of 172 co-authors. Here are the top co-authors by number of shared publications:
Hiroshi Date
Department of Thoracic Surgery, Kyoto University Hospital, Kyoto, Japan
9 shared publicationsMakoto Sonobe
Department of Thoracic Surgery, Osaka Red Cross Hospital, Osaka, Japan
8 shared publications- Masatsugu Hamaji
Department of Thoracic and Cardiovascular Surgery, Nara Medical University, Kashihara, Japan
8 shared publications - Toshi Menju
Department of Thoracic Surgery, Graduate School of Medicine, Kyoto University, Kyoto, Japan
7 shared publications Akihiro Aoyama
Department of Thoracic Surgery, Kyoto Katsura Hospital, Kyoto, Japan
6 shared publications- Hiroshi Date
Department of Thoracic Surgery, Graduate School of Medicine, Kyoto University, Kyoto, Japan
6 shared publications
Latest Publications
- Open Access
Clinical-to-Pathological Nodal Discordance and Postoperative Outcomes by EGFR Mutation Subtype in Resected Clinically Node-Positive Non-Small-Cell Lung Cancer
Background/Objectives: Clinical nodal classification may differ from postoperative pathological findings in lung cancer. We evaluated nodal discordance and mutation-specific outcomes in surgically treated, clinically node-positive epidermal growth factor receptor (EGFR)-mutant non-small-cell lung cancer. Methods: This retrospective study included patients with clinical N1–2, stage II–III disease treated at four Japanese institutions from 2012 to 2020. EGFR exon 19 deletion (Del19) and exon 21 L858R point mutation (L858R) were compared in exploratory postoperative and post-recurrence survival analyses. Results: Among 66 patients, 33 had Del19, 28 had L858R, and 5 had uncommon mutations; 52 underwent upfront surgery and 14 received preoperative treatment. Among 42 patients with clinical N1 disease, 18 (42.9%) had postoperative pathological N2 disease. The adjusted hazard ratio for postoperative overall survival with L858R versus Del19 was 1.99 (95% confidence interval, 0.97–4.09); the corresponding progression-free survival hazard ratio was 0.99 (0.54–1.81). In the pooled pathological common-mutation cohort, post-recurrence overall survival was evaluated in 33 patients with 25 deaths (univariable hazard ratio, 1.41; 95% confidence interval, 0.64–3.11; log-rank p = 0.388). Post-recurrence progression-free survival was evaluated in 26 patients and favored Del19 in an unadjusted comparison (log-rank p = 0.023). Conclusions: Nodal discordance was frequent in this selected surgical population. The imprecise survival estimates establish neither equivalent prognosis nor an independent adverse effect of L858R. Post-recurrence findings require external validation with treatment-adjusted analyses.
Open AccessClinical-to-Pathological Nodal Discordance and Postoperative Outcomes by EGFR Mutation Subtype in Resected Clinically Node-Positive Non-Small-Cell Lung Cancer
Background/Objectives: Clinical nodal classification may differ from postoperative pathological findings in lung cancer. We evaluated nodal discordance and mutation-specific outcomes in surgically treated, clinically node-positive epidermal growth factor receptor (EGFR)-mutant non-small-cell lung cancer. Methods: This retrospective study included patients with clinical N1–2, stage II–III disease treated at four Japanese institutions from 2012 to 2020. EGFR exon 19 deletion (Del19) and exon 21 L858R point mutation (L858R) were compared in exploratory postoperative and post-recurrence survival analyses. Results: Among 66 patients, 33 had Del19, 28 had L858R, and 5 had uncommon mutations; 52 underwent upfront surgery and 14 received preoperative treatment. Among 42 patients with clinical N1 disease, 18 (42.9%) had postoperative pathological N2 disease. The adjusted hazard ratio for postoperative overall survival with L858R versus Del19 was 1.99 (95% confidence interval, 0.97–4.09); the corresponding progression-free survival hazard ratio was 0.99 (0.54–1.81). In the pooled pathological common-mutation cohort, post-recurrence overall survival was evaluated in 33 patients with 25 deaths (univariable hazard ratio, 1.41; 95% confidence interval, 0.64–3.11; log-rank p = 0.388). Post-recurrence progression-free survival was evaluated in 26 patients and favored Del19 in an unadjusted comparison (log-rank p = 0.023). Conclusions: Nodal discordance was frequent in this selected surgical population. The imprecise survival estimates establish neither equivalent prognosis nor an independent adverse effect of L858R. Post-recurrence findings require external validation with treatment-adjusted analyses.
- 12 December 2025
- Published by Georg Thieme Verlag KG in The Thoracic and Cardiovascular Surgeon
- Vol. 74 (05) , 430-432
Postoperative Recurrence of ROS1-Rearranged Lung Adenocarcinoma: A Case Series
Postoperative recurrence of c-ros oncogene 1 (ROS1)-rearranged non-small cell lung cancer is rarely reported, and the role of tyrosine kinase inhibitors (TKIs) remains unclear. We retrospectively reviewed four patients with completely resected ROS1-positive lung adenocarcinoma who developed recurrence, three receiving crizotinib. The median disease-free interval was 33.4 months, and the median overall survival from postoperative recurrence and initial surgery was 40.7 and 71.2 months, respectively. Brain metastases were the most common initial recurrence site (75%). Crizotinib showed limited efficacy with a median progression-free survival of 3.5 months. These findings highlight indolent disease behavior but limited TKI benefit, supporting the need for adjuvant trials.
- 12 December 2025
- Published by Georg Thieme Verlag KG in The Thoracic and Cardiovascular Surgeon
- Vol. 74 (05) , 430-432
Postoperative Recurrence of ROS1-Rearranged Lung Adenocarcinoma: A Case Series
Postoperative recurrence of c-ros oncogene 1 (ROS1)-rearranged non-small cell lung cancer is rarely reported, and the role of tyrosine kinase inhibitors (TKIs) remains unclear. We retrospectively reviewed four patients with completely resected ROS1-positive lung adenocarcinoma who developed recurrence, three receiving crizotinib. The median disease-free interval was 33.4 months, and the median overall survival from postoperative recurrence and initial surgery was 40.7 and 71.2 months, respectively. Brain metastases were the most common initial recurrence site (75%). Crizotinib showed limited efficacy with a median progression-free survival of 3.5 months. These findings highlight indolent disease behavior but limited TKI benefit, supporting the need for adjuvant trials.
- 4 December 2025
- Published by Springer Nature in Surgery Today
- Vol. 56 (7) , 1431-1435
Survival outcomes of alectinib in postoperative recurrent ALK-rearranged lung cancer
The clinical benefits of anaplastic lymphoma kinase (ALK) inhibitors in patients with recurrent ALK-rearranged lung adenocarcinoma after surgical resection remain poorly understood. We retrospectively reviewed the medical records of 10 patients who received alectinib as first-line therapy for postoperative recurrence between 2014 and 2018, following complete resection at multiple institutions in Japan. Clinical outcomes, including the progression-free survival (PFS) and overall survival (OS), were analyzed. The median follow-up duration was 93.6 months from surgery. The median OS was 96.8 months after surgery and 82.8 months from recurrence. The median PFS from recurrence was not reached, with a 5-year PFS rate of 58.3%. One patient discontinued treatment because of adverse events. Alectinib, as a first-line therapy for recurrent ALK-rearranged lung adenocarcinoma, demonstrated durable efficacy and acceptable safety. These findings suggest that targeted therapy for recurrence is a valuable treatment strategy. Prospective studies are warranted to determine the optimal timing for ALK-TKI initiation.
- 4 December 2025
- Published by Springer Nature in Surgery Today
- Vol. 56 (7) , 1431-1435
Survival outcomes of alectinib in postoperative recurrent ALK-rearranged lung cancer
The clinical benefits of anaplastic lymphoma kinase (ALK) inhibitors in patients with recurrent ALK-rearranged lung adenocarcinoma after surgical resection remain poorly understood. We retrospectively reviewed the medical records of 10 patients who received alectinib as first-line therapy for postoperative recurrence between 2014 and 2018, following complete resection at multiple institutions in Japan. Clinical outcomes, including the progression-free survival (PFS) and overall survival (OS), were analyzed. The median follow-up duration was 93.6 months from surgery. The median OS was 96.8 months after surgery and 82.8 months from recurrence. The median PFS from recurrence was not reached, with a 5-year PFS rate of 58.3%. One patient discontinued treatment because of adverse events. Alectinib, as a first-line therapy for recurrent ALK-rearranged lung adenocarcinoma, demonstrated durable efficacy and acceptable safety. These findings suggest that targeted therapy for recurrence is a valuable treatment strategy. Prospective studies are warranted to determine the optimal timing for ALK-TKI initiation.
- Open Access
- 28 May 2024
- Published by Elsevier in Annals of Thoracic Surgery Short Reports
- Vol. 2 (3) , 469-473
Adjuvant Chemotherapy After Neoadjuvant Therapy and Surgery for Non-Small Cell Lung Cancer
- 28 May 2024
- Published by Elsevier in Annals of Thoracic Surgery Short Reports
- Vol. 2 (3) , 469-473
Open AccessAdjuvant Chemotherapy After Neoadjuvant Therapy and Surgery for Non-Small Cell Lung Cancer
- Open Access
- 26 January 2024
- Published by Editorial Committee of Annals of Thoracic and Cardiovascular Surgery in Annals of Thoracic and Cardiovascular Surgery
- Vol. 30 (1)
Effect of Tegafur–Uracil in Resected Stage IB Lung Adenocarcinoma According to Presence or Absence of Epidermal Growth Factor Receptor Gene Mutation: A Retrospective Cohort Study
Purpose: Tegafur–uracil (UFT) is the standard postoperative adjuvant therapy for stage IB lung adenocarcinoma (LUAD) in Japan. This study aimed to determine whether UFT is effective in stage IB LUAD with and without epidermal growth factor receptor (EGFR) mutations.Methods: This retrospective study included 169 patients with stage IB LUAD who underwent complete resection at our department between 2010 and 2021. We investigated the clinicopathological and prognostic impact of EGFR mutations as well as the postoperative use of UFT.Results: EGFR mutation-positive cases tended to show a higher cumulative recurrence rate than EGFR mutation-negative cases (p = 0.081), while overall survival was comparable between the groups (p = 0.238). In the entire cohort, UFT administration was not an independent prognostic factor in the multivariate regression analysis (p = 0.112). According to a stratification analysis, UFT administration was independently associated with favorable overall survival (p = 0.031) in EGFR mutation-negative cases, while it was not associated with recurrence-free survival (p = 0.991) or overall survival (p = 0.398) in EGFR mutation-positive cases.Conclusion: UFT administration can improve the prognosis of EGFR mutation-negative LUAD but not EGFR mutation-positive LUAD. Thus, clinical trials of adjuvant-targeted therapy for EGFR mutation-positive stage IB LUAD should also be conducted in Japan.
- 26 January 2024
- Published by Editorial Committee of Annals of Thoracic and Cardiovascular Surgery in Annals of Thoracic and Cardiovascular Surgery
- Vol. 30 (1)
Open AccessEffect of Tegafur–Uracil in Resected Stage IB Lung Adenocarcinoma According to Presence or Absence of Epidermal Growth Factor Receptor Gene Mutation: A Retrospective Cohort Study
Purpose: Tegafur–uracil (UFT) is the standard postoperative adjuvant therapy for stage IB lung adenocarcinoma (LUAD) in Japan. This study aimed to determine whether UFT is effective in stage IB LUAD with and without epidermal growth factor receptor (EGFR) mutations.Methods: This retrospective study included 169 patients with stage IB LUAD who underwent complete resection at our department between 2010 and 2021. We investigated the clinicopathological and prognostic impact of EGFR mutations as well as the postoperative use of UFT.Results: EGFR mutation-positive cases tended to show a higher cumulative recurrence rate than EGFR mutation-negative cases (p = 0.081), while overall survival was comparable between the groups (p = 0.238). In the entire cohort, UFT administration was not an independent prognostic factor in the multivariate regression analysis (p = 0.112). According to a stratification analysis, UFT administration was independently associated with favorable overall survival (p = 0.031) in EGFR mutation-negative cases, while it was not associated with recurrence-free survival (p = 0.991) or overall survival (p = 0.398) in EGFR mutation-positive cases.Conclusion: UFT administration can improve the prognosis of EGFR mutation-negative LUAD but not EGFR mutation-positive LUAD. Thus, clinical trials of adjuvant-targeted therapy for EGFR mutation-positive stage IB LUAD should also be conducted in Japan.
- Open Access
- 24 January 2024
- Published by Wiley in Respirology Case Reports
- Vol. 12 (1) , e01286
A case of attempted transbronchial spigot insertion for fistulous pyothorax in the residual pleural airspace after pleurectomy/decortication for malignant pleural mesothelioma
Pleurectomy/decortication for malignant pleural mesothelioma is a relatively recent surgical approach for which there is a dearth of information on complications, especially in the late postoperative period. A 70‐year‐old man was diagnosed with right epithelioid malignant pleural mesothelioma and underwent pleurectomy/decortication. Computed tomography at 6 months after surgery revealed nodules on the surface of the right lung. These nodules gradually increased in size and were diagnosed as recurrent disease. Immunotherapy was started, but treatment was discontinued a few days after the first course due to pneumonitis. Subsequent oral prednisolone therapy for about 2 months ameliorated pneumonitis, but fistulous pyothorax developed. During attempted transbronchial occlusion of the responsible bronchus, some spigots penetrated the empyema cavity. Open window thoracotomy was performed on the following day. This case suggests that if there is no change in diameter between the proximal and distal parts of the responsible bronchus, transbronchial occlusion should not be chosen.
- 24 January 2024
- Published by Wiley in Respirology Case Reports
- Vol. 12 (1) , e01286
Open AccessA case of attempted transbronchial spigot insertion for fistulous pyothorax in the residual pleural airspace after pleurectomy/decortication for malignant pleural mesothelioma
Pleurectomy/decortication for malignant pleural mesothelioma is a relatively recent surgical approach for which there is a dearth of information on complications, especially in the late postoperative period. A 70‐year‐old man was diagnosed with right epithelioid malignant pleural mesothelioma and underwent pleurectomy/decortication. Computed tomography at 6 months after surgery revealed nodules on the surface of the right lung. These nodules gradually increased in size and were diagnosed as recurrent disease. Immunotherapy was started, but treatment was discontinued a few days after the first course due to pneumonitis. Subsequent oral prednisolone therapy for about 2 months ameliorated pneumonitis, but fistulous pyothorax developed. During attempted transbronchial occlusion of the responsible bronchus, some spigots penetrated the empyema cavity. Open window thoracotomy was performed on the following day. This case suggests that if there is no change in diameter between the proximal and distal parts of the responsible bronchus, transbronchial occlusion should not be chosen.
- 23 August 2022
- Published by Oxford University Press (OUP) in European Journal of Cardio-Thoracic Surgery
- Vol. 62 (5)
Epidermal growth factor receptor tyrosine kinase inhibitors as first-line treatment for postoperative recurrent EGFR-mutated lung adenocarcinoma: a multi-institutional retrospective study
To analyze the long-term survival outcomes and prognostic factors of patients receiving epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) as first-line treatment for postoperative recurrent EGFR-mutated lung adenocarcinoma. Using a multi-institutional database, we performed a retrospective chart review to identify all patients who had undergone complete resection of stage I-III EGFR-mutated lung adenocarcinoma at 11 acute care hospitals between 2009 and 2016, and had received first-line EGFR-TKI treatment for postoperative recurrence. Adverse events, progression-free survival (PFS), and overall survival (OS) were investigated. Survival outcomes were assessed using Kaplan–Meier analysis. Cox proportional hazards models were used to calculate the hazard ratios (HRs) and 95% confidence intervals (CIs) for PFS and OS. The study sample comprised 154 patients with a median age of 69. The total numbers of events were 101 for PFS and 60 for OS. The median PFS and OS were 26.1 months and 55.4 months, respectively. In the multivariable analysis, EGFR ex 21 L858R mutation (HR: 1.71, 95% CI: 1.15–2.55) and shorter disease-free intervals (HR: 0.98, 95% CI: 0.96–0.99) were significantly associated with shorter PFS. Age (HR: 1.03, 95% CI: 1.00–1.07), smoking history (HR: 2.31, 95% CI: 1.35–3.94) and pathological N2 disease at the initial surgery (HR: 2.30, 95% CI: 1.32–4.00) were significantly associated with shorter OS. First-line EGFR-TKI treatment was generally associated with favorable survival outcomes in patients with postoperative recurrent EGFR-mutated lung adenocarcinoma. EGFR ex 21 L858R mutation may be an important prognostic factor for shorter PFS.
- 23 August 2022
- Published by Oxford University Press (OUP) in European Journal of Cardio-Thoracic Surgery
- Vol. 62 (5)
Epidermal growth factor receptor tyrosine kinase inhibitors as first-line treatment for postoperative recurrent EGFR-mutated lung adenocarcinoma: a multi-institutional retrospective study
To analyze the long-term survival outcomes and prognostic factors of patients receiving epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) as first-line treatment for postoperative recurrent EGFR-mutated lung adenocarcinoma. Using a multi-institutional database, we performed a retrospective chart review to identify all patients who had undergone complete resection of stage I-III EGFR-mutated lung adenocarcinoma at 11 acute care hospitals between 2009 and 2016, and had received first-line EGFR-TKI treatment for postoperative recurrence. Adverse events, progression-free survival (PFS), and overall survival (OS) were investigated. Survival outcomes were assessed using Kaplan–Meier analysis. Cox proportional hazards models were used to calculate the hazard ratios (HRs) and 95% confidence intervals (CIs) for PFS and OS. The study sample comprised 154 patients with a median age of 69. The total numbers of events were 101 for PFS and 60 for OS. The median PFS and OS were 26.1 months and 55.4 months, respectively. In the multivariable analysis, EGFR ex 21 L858R mutation (HR: 1.71, 95% CI: 1.15–2.55) and shorter disease-free intervals (HR: 0.98, 95% CI: 0.96–0.99) were significantly associated with shorter PFS. Age (HR: 1.03, 95% CI: 1.00–1.07), smoking history (HR: 2.31, 95% CI: 1.35–3.94) and pathological N2 disease at the initial surgery (HR: 2.30, 95% CI: 1.32–4.00) were significantly associated with shorter OS. First-line EGFR-TKI treatment was generally associated with favorable survival outcomes in patients with postoperative recurrent EGFR-mutated lung adenocarcinoma. EGFR ex 21 L858R mutation may be an important prognostic factor for shorter PFS.
- Open Access
- 15 October 2021
- Published by Oxford University Press (OUP) in Interactive CardioVascular and Thoracic Surgery
- Vol. 34 (3) , 416-423
Epidermal growth factor receptor (EGFR)—tyrosine kinase inhibitors as a first-line treatment for postoperative recurrent and EGFR-mutated non-small-cell lung cancer
To clarify survival outcomes and prognostic factors of patients receiving epidermal growth factor receptor (EGFR) - tyrosine kinase inhibitors (TKIs) as first-line treatment for postoperative recurrence. A retrospective chart review was performed to identify consecutive patients who received EGFR-TKIs as first-line treatment for postoperative recurrence of non-small-cell lung cancer (NSCLC) harbouring EGFR gene mutations at our institution between August 2002 and October 2020. Therapeutic response, adverse events, progression-free survival (PFS) and overall survival (OS) were investigated. Survival outcomes were assessed using the Kaplan–Meier analysis. The Cox proportional hazards model was used for univariable and multivariable analyses. Sixty-four patients were included in the study. The objective response and disease control rates were 53% and 92%, respectively. Grade 3 or greater adverse events were noted in 4 (6.3%) patients, including 1 patient (1.6%) of interstitial pneumonia. The median follow-up period was 28.5 months (range 3–202 months). The total number of events was 43 for PFS and 23 for OS, respectively. The median PFS was 18 months, and the median OS was 61 months after EGFR-TKI treatment. In multivariable analysis, osimertinib showed a tendency to prolong PFS [hazard ratio (HR) 0.41, 95% confidence interval (CI) 0.12–1.1; P = 0.071], whereas the micropapillary component was significantly associated with shorter OS (HR 2.1, 95% CI 1.02–6.9; P = 0.045). EGFR-TKIs as first-line treatment appeared to be a reasonable treatment option in selected patients with postoperative recurrent EGFR-mutated NSCLC. Osimertinib and the micropapillary component may be prognostic factors.
- 15 October 2021
- Published by Oxford University Press (OUP) in Interactive CardioVascular and Thoracic Surgery
- Vol. 34 (3) , 416-423
Open AccessEpidermal growth factor receptor (EGFR)—tyrosine kinase inhibitors as a first-line treatment for postoperative recurrent and EGFR-mutated non-small-cell lung cancer
To clarify survival outcomes and prognostic factors of patients receiving epidermal growth factor receptor (EGFR) - tyrosine kinase inhibitors (TKIs) as first-line treatment for postoperative recurrence. A retrospective chart review was performed to identify consecutive patients who received EGFR-TKIs as first-line treatment for postoperative recurrence of non-small-cell lung cancer (NSCLC) harbouring EGFR gene mutations at our institution between August 2002 and October 2020. Therapeutic response, adverse events, progression-free survival (PFS) and overall survival (OS) were investigated. Survival outcomes were assessed using the Kaplan–Meier analysis. The Cox proportional hazards model was used for univariable and multivariable analyses. Sixty-four patients were included in the study. The objective response and disease control rates were 53% and 92%, respectively. Grade 3 or greater adverse events were noted in 4 (6.3%) patients, including 1 patient (1.6%) of interstitial pneumonia. The median follow-up period was 28.5 months (range 3–202 months). The total number of events was 43 for PFS and 23 for OS, respectively. The median PFS was 18 months, and the median OS was 61 months after EGFR-TKI treatment. In multivariable analysis, osimertinib showed a tendency to prolong PFS [hazard ratio (HR) 0.41, 95% confidence interval (CI) 0.12–1.1; P = 0.071], whereas the micropapillary component was significantly associated with shorter OS (HR 2.1, 95% CI 1.02–6.9; P = 0.045). EGFR-TKIs as first-line treatment appeared to be a reasonable treatment option in selected patients with postoperative recurrent EGFR-mutated NSCLC. Osimertinib and the micropapillary component may be prognostic factors.
- 21 June 2021
- Published by Oxford University Press (OUP) in Interactive CardioVascular and Thoracic Surgery
- Vol. 33 (2) , 242-249
Lymph node dissection in thymic carcinomas and neuroendocrine carcinomas
OBJECTIVES: Although lymph node (LN) metastases are not uncommon in thymic carcinomas, preoperative LN evaluation, intraoperative lymph node dissection (LND) and postoperative outcomes remain unknown. The aim of this study was to elucidate the characteristics of and outcomes in patients with thymic carcinomas and thymic neuroendocrine carcinomas undergoing LND. METHODS: A retrospective chart review was performed using our multi-institutional database to identify patients who underwent resection and LND for thymic carcinoma or thymic neuroendocrine carcinoma between 1991 and 2018. An enlarged mediastinal LN was defined as having a short-axis diameter >1 cm. We assessed survival outcomes using the Kaplan–Meier analysis. RESULTS: N1-level LND was performed in 41 patients (54.6%), N2-level LND in 14 patients (18.7%) and both-level LND in 16 patients (21.3%). Pathological LN metastasis was detected in 20 patients (26.7%) among the 75 patients undergoing LND. There was a significant difference in the number of LN stations (P = 0.015) and metastasis factor (P = 0.0042) between pathologically LN-positive and pathologically LN-negative patients. The sensitivity of enlarged LNs on preoperative computed tomography was 18.2%. There was a tendency towards worse overall survival of pathologically N2-positive patients, although the difference was not statistically significant (P = 0.15). CONCLUSIONS: Preoperative CT appears to play a limited role in detecting pathological LN metastases. Our findings suggest that the significance of N1- and N2-level LND should be evaluated in prospective studies to optimize the postoperative management of patients with thymic carcinomas and neuroendocrine carcinomas.
- 21 June 2021
- Published by Oxford University Press (OUP) in Interactive CardioVascular and Thoracic Surgery
- Vol. 33 (2) , 242-249
Lymph node dissection in thymic carcinomas and neuroendocrine carcinomas
OBJECTIVES: Although lymph node (LN) metastases are not uncommon in thymic carcinomas, preoperative LN evaluation, intraoperative lymph node dissection (LND) and postoperative outcomes remain unknown. The aim of this study was to elucidate the characteristics of and outcomes in patients with thymic carcinomas and thymic neuroendocrine carcinomas undergoing LND. METHODS: A retrospective chart review was performed using our multi-institutional database to identify patients who underwent resection and LND for thymic carcinoma or thymic neuroendocrine carcinoma between 1991 and 2018. An enlarged mediastinal LN was defined as having a short-axis diameter >1 cm. We assessed survival outcomes using the Kaplan–Meier analysis. RESULTS: N1-level LND was performed in 41 patients (54.6%), N2-level LND in 14 patients (18.7%) and both-level LND in 16 patients (21.3%). Pathological LN metastasis was detected in 20 patients (26.7%) among the 75 patients undergoing LND. There was a significant difference in the number of LN stations (P = 0.015) and metastasis factor (P = 0.0042) between pathologically LN-positive and pathologically LN-negative patients. The sensitivity of enlarged LNs on preoperative computed tomography was 18.2%. There was a tendency towards worse overall survival of pathologically N2-positive patients, although the difference was not statistically significant (P = 0.15). CONCLUSIONS: Preoperative CT appears to play a limited role in detecting pathological LN metastases. Our findings suggest that the significance of N1- and N2-level LND should be evaluated in prospective studies to optimize the postoperative management of patients with thymic carcinomas and neuroendocrine carcinomas.
- Open Access
- 1 June 2021
- Published by Elsevier in Otolaryngology Case Reports
- Vol. 19, 100283
Treating radiation-induced sarcoma of the head and neck: A case report
- 1 June 2021
- Published by Elsevier in Otolaryngology Case Reports
- Vol. 19, 100283
Open AccessTreating radiation-induced sarcoma of the head and neck: A case report